| 2007-10-02: |
Mylan Completes Acquisition of Generics Business of Merck KGaA
Pittsburgh ( PRN/ots ) - Mylan ( NYSE: MYL ) announced today that it has completed its acquisition of Merck KGaA's generics business ( "Merck Generics" ) to become one of the largest quality generics and specialty pharmaceuticals companies in the world. Mylan and Merck KGaA initially announced the (...) |
| 2007-10-02: |
International Survey Shows People Over Forty Ignore Risk of Blindness
London ( PRN/ots ) - - Global Advocacy Groups Launch Joint Effort to Preserve Eyesight of Millions At - Risk for Glaucoma Results of a new international survey reveal that eye exams are being ignored by many aged over 40. Only two fifths of respondents had (...) |
| 2007-10-01: |
Centrally acting analgesic tapentadol - latest phase II data for the treatment of acute postoperative pain presented
Aachen ( na Originaltextservice ) - At this year's 4th World Congress of the World Institute of Pain ( WIP ), the German pharmaceutical company Grunenthal GmbH presented the latest clinical data on its centrally active analgesic tapentadol in acute pain. Tapentadol combines two analgesic principles in one (...) |
| 2007-10-01: |
Could You Have Hepatitis? New Report Shows That the Majority of Europeans With Hepatitis C Remain Undiagnosed
Brussels, Belgium ( PRN/ots ) - - European Liver Patients Association Urges People at Risk to get Tested! A report( 1 ) released today by the Eurasian Harm Reduction Network ( EHRN )( i ) highlights the significant inconsistencies that exist in hepatitis C ( HCV ) diagnosis and treatment across Europe (...) |
| 2007-09-28: |
Eisai Announce Application to Appeal NICE Judicial Review Verdict
London ( PRN/ots ) - Eisai Limited, the licence holder of Aricept( R ) ( donepezil hydrochloride ) and Pfizer Limited, its co - promotion partner, announced today that Eisai has applied to the Court of Appeal for permission to appeal the recent High Court ruling on the process by which (...) |
| 2007-09-28: |
Eisai Announce Establishment of New Pharmaceutical Marketing Subsidiary in Belgium
London ( PRN/ots ) - - For the Attention of Business and Healthcare Editors Eisai Co., Ltd. ( Headquarters: Tokyo, President & CEO: Haruo Naito ) announced today that the Company established its pharmaceutical marketing subsidiary, Eisai SA/NV in Belgium. Eisai SA/NV is owned by (...) |
| 2007-09-27: |
New Report Says a Pandemic is Overdue, But Companies and Nations are ill Prepared to Cope With the Impact
Las Vegas, Nevada ( PRN/ots ) - - Ten Best Practices Offered to Overcome 'Pandemic Fatigue' A new report issued today by Marsh and The Albright Group, two of the world's foremost risk experts, warns that the catastrophic impacts of a long - lasting pandemic (...) |
| 2007-09-26: |
New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid - Induced Bowel Dysfunction in Patients With Chronic Severe Pain
Cambridge, England ( PRN/ots ) - - New Approach in the Development of Opioid - Based Pain Management Therapy Improves Bowel Function The oral prolonged - release ( PR ) oxycodone / naloxone combination tablet reduces opioid - induced bowel dysfunction in patients with chronic severe pain compared to treatment with (...) |
| 2007-09-26: |
Herceptin Eradicates Tumours and may Reduce the Need for Mastectomies in Women With Inflammatory HER2 - Positive Breast Cancer - one of the Most Aggressive and Fastest Growing Forms of the Disease
Barcelona, Spain ( PRN/ots ) - - Abstract no: 2030, Being Presented at ECCO in the "Proffered Papers: Breast Cancer - Early Disease" Session in the Forum, Starting at 09.00am on Wednesday 26th September 2007 - For non - US Media Only New data show that the (...) |
| 2007-09-26: |
Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications
Boxmeer, The Netherlands and London ( PRN/ots ) - Nobilon International B.V., part of Organon, the human health care business unit of Akzo Nobel, and Protherics PLC, the international biopharmaceutical company focused on critical care and cancer, today announced that Nobilon has licensed Protherics' CoVaccine HT( TM ) adjuvant (...) |
| 2007-09-26: |
European Expert Consortium Combines Forces to Develop a Novel Pandemic Influenza Vaccine
Boxmeer, The Netherlands ( PRN/ots ) - A consortium of experts in the field of human virus research and vaccine development have joined forces to develop a novel pandemic influenza vaccine as a potential emergency vaccination. The four - year project has been awarded a grant of (...) |
| 2007-09-25: |
Siemens Medical Solutions Diagnostics Launches the DCA Vantage Analyzer for Point - of - care Diabetes Management
Tarrytown, New York ( PRN/ots ) - - Advanced Network - Ready Diabetes Analysis for Better Patient Management Siemens Medical Solutions Diagnostics ( www.siemens.com/diagnostics ) today announced the launch of the DCA Vantage( TM ) Analyzer, a point - of - care ( POC ) diabetes patient management platform providing glycosylated hemoglobin ( HbA1c ), Microalbumin/Creatinine (...) |
| 2007-09-25: |
New Data Shows Bowel Cancer Patients Live Longer on Xeloda
Barcelona, Spain ( PRN/ots ) - Abstract no: 1LB, being presented at ECCO "Gastrointestinal malignancies - colorectal cancer 1" session in room 110, starting at 09.00 on Tuesday 25 September 2007 BARCELONA, Spain, September 25 /PRNewswire/ - - - 5 Year Data Confirm Superiority of Xeloda Over (...) |
| 2007-09-25: |
New Data Shows Bowel Cancer Patients Live Longer on Xeloda
Barcelona, Spain ( PRN/ots ) - Abstract no: 1LB, being presented at ECCO "Gastrointestinal malignancies - colorectal cancer 1" session in room 110, starting at 09.00 on Tuesday 25 September 2007 BARCELONA, Spain, September 25 /PRNewswire/ - - - 5 Year Data Confirm Superiority of Xeloda Over (...) |
| 2007-09-24: |
Avastin Achieves Impressive Rate of Curative Surgery in Patients With Advanced Colorectal Cancer
Barcelona, Spain ( PRN/ots ) - - Largest Series of Patients With Successful Surgery Reported in Large, Prospective Clinical Trial - Abstract no: 3020, Being Presented at ECCO in Room 115 - 116, Starting at 12:15 on Monday 24th September 2007 - For non - US Media (...) |
| 2007-09-23: |
New Global Survey Highlights Deep Psychological Impact of Breast Cancer Recurrence on Both Patients and Physicians
Barcelona ( PRN/ots ) - - For Medical and Healthcare Media Only - FOR INTERNATIONAL JOURNALISTS - NOT FOR US MEDIA - Data Highlight the Need for More Positive Conversations Through Better Communication, Training and Use of Effective Treatments A devastating moment for a woman undergoing (...) |
| 2007-09-20: |
European Committee Issues Positive Opinion on Wyeth's TORISEL( TM ) for Advanced Renal Cell Carcinoma
Collegeville, Pennsylvania ( PRN/ots ) - - European Committee Issues Negative Opinion on MYLOTARG( R ) for Acute Myeloid Leukemia; Wyeth Plans to Appeal Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), announced today that it has received a positive opinion from the Committee for Medicinal Products (...) |
| 2007-09-20: |
Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer
New York ( PRN/ots ) - Callisto Pharmaceuticals, Inc. ( Amex: KAL; FWB: CA4 ), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders and diseases, announced today that complete enrollment of its Phase II clinical trial of Atiprimod to treat low (...) |
| 2007-09-19: |
New Data Confirm Clear Benefit of Protelos( R ) ( Strontium Ranelate ) in the Treatment of Postmenopausal Osteoporosis
Honolulu, Hawaii ( PRN/ots ) - - Protelos( R ) Relaunches Bone Formation and Increases Bone Volume in Patients on Long Term Bisphosphonate Treatment Protelos( R ) ( strontium ranelate ) stimulates bone formation and increases bone volume by 30 Prozent in high fracture risk patients who have been on long term (...) |
| 2007-09-19: |
New Research Shows ACTOS( R ) ( pioglitazone HCI ) is Associated With a 38 Prozent Lower Risk of Heart Attack in Type 2 Diabetes
Amsterdam ( PRN/ots ) - - For Non - US Media Only New research, including two studies presented this week at the 43rd Annual Meeting of the European Association for the Study of Diabetes ( EASD ), further support the cardiovascular safety of ACTOS( R ) ( pioglitazone HCI ) and its (...) |
| 2007-09-19: |
Simplify pain management by calculating the Medication Quantification Scale ( MQS ) online / The P.A.I.N. Initiative presents the first web - based tool for the quantification of pain medication
Aachen ( na Originaltextservice ) - With the Medication Quantification Scale ( MQS ) Online Calculator, the P.A.I.N. ( Pain Associates' International Network ) Initiative by the German pharmaceutical company Grunenthal GmbH offers a web - based tool for the quantification of medication used in pain populations. The MQS (...) |
| 2007-09-18: |
Actonel Halves Risk of Fracture in Osteoporotic Women With History of Hip Fracture
Honolulu, Hawaii ( PRN/ots ) - New data show that Actonel( R ) 5mg ( risedronate sodium tablets ) reduces the risk of clinical fractures by half versus placebo over three years in postmenopausal women with osteoporosis who have suffered a previous hip fracture( 1 ) - a group of patients at (...) |
| 2007-09-13: |
Roche Launches Another Large Study With PEGASYS Plus COPEGUS
Basel, Switzerland ( PRN/ots ) - - PROPHESYS Will Identify Factors That Influence Early Response to Treatment Roche announces the start of a large multinational observational study, called PROPHESYS, in patients with hepatitis C ( HCV ). This international cohort study will evaluate the important factors that give (...) |
| 2007-09-06: |
AstraZeneca Announces First Patient Enrolled in Head - to - Head Comparison of CRESTOR/Ezetimibe With Simvastatin/Ezetimibe
London ( PRN/ots ) - AstraZeneca today announced enrolment of the first patient in the new GRAVITY study ( Gauging the lipid effects of RosuvAstatin plus ezetimibe Versus sImvastatin plus ezetimibe TherapY ). GRAVITY is a clinical trial examining the impact on LDL - cholesterol ( 'bad' cholesterol ) levels in (...) |
| 2007-09-06: |
Boehringer Ingelheim to Initiate First Phase III Pivotal Study for New Oncology Compound BIBW 2992( i )
Ingelheim, Germany ( PRN/ots ) - - New Data on BIBW 2992( i ), a Potent, Irreversible, Second - Generation Oral Signal Transduction Inhibitor Provides Glimpse of Next Chapter in Lung Cancer Care - For Non - US Media Boehringer Ingelheim announced today from the 12th World Conference on Lung (...) |
| 2007-09-05: |
Pieris validates the use of Anticalins® as ophthalmologic biotherapeutics
Freising - Weihenstephan, Germany ( na Originaltextservice ) - Pieris AG, a bio - pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, today announced successful completion of a series of preclinical studies validating the use of Anticalins® in ophthalmologic disease. The (...) |
| 2007-09-03: |
Suffering in Silence - The Real Impact of the Last Taboo
Ingelheim, Germany ( PRN/ots ) - Constipation is a condition that we are all familiar with, however, according to new international research from Dulcolax( R ), constipation actually affects much more than just bowel movements and can have a severely detrimental impact on people's quality of life, in (...) |
| 2007-09-03: |
New Study Findings Confirm CLEXANE( R )/LOVENOX( R ) Long - Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Paris ( PRN/ots ) - Sanofi - aventis announced today that one year findings from the landmark ExTRACT - TIMI 25 and STEEPLE studies confirm clear net clinical benefit for patients with acute ST - segment elevation myocardial infarction ( STEMI ) for Lovenox( R ) vs Unfractionnated Heparin ( UFH ). The ExTRACT - TIMI (...) |
| 2007-08-29: |
American Stock Exchange Accepts Callisto Pharamceuticals' Plan of Compliance and Extension to Regain Compliance with Standards
New York ( PRN/ots ) - Callisto Pharmaceuticals, Inc. ( Amex: KAL; FWB: CA4 ), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders and diseases, today announced that the staff of the American Stock Exchange ( "AMEX" ) has reviewed the Company's plan (...) |
| 2007-08-29: |
AstraZeneca's Once - Daily SEROQUEL XR( TM ) Extended - Release Tablets Approved in Netherlands for the Acute and Long Term Treatment of Schizophrenia
London ( PRN/ots ) - - For International Medical Journalists Only AstraZeneca today announced the Netherlands regulatory authority MEB ( Medicines Evaluation Board ) has approved SEROQUEL XR( TM ) ( quetiapine fumarate ) Extended - Release Tablets, a once - daily medicine for the treatment of schizophrenia in adult patients. With SEROQUEL XR( TM ) (...) |
| 2007-08-24: |
AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
Minneapolis ( PRN/ots ) - AGA Medical Corporation ( "AGA" ) announced today that it has received U.S. Food and Drug Administration ( FDA ) and European CE Mark approvals for the AMPLATZER Vascular Plug II ( "vascular plug II" ). The AMPLATZER Vascular Plug II expands the AGA (...) |
| 2007-08-24: |
Avastin Approved in Europe for First - line Treatment of Patients With Advanced Lung Cancer
Basel, Switzerland ( PRN/ots ) - - First Medicine Shown to Extend Survival Beyond One Year in Previously Untreated Lung Cancer Patients Avastin ( bevacizumab ), Roche's innovative anti - cancer drug, was approved today in Europe for the first - line treatment of patients with advanced non - small (...) |
| 2007-08-22: |
Updated WHO Bird Flu ( H5N1 ) Management Guidance Reinforces Tamiflu as First Line Treatment
Basel, Switzerland ( PRN/ots ) - The World Health Organization ( WHO ) has reinforced that Tamiflu ( oseltamivir ) is the primary recommended antiviral of choice in managing patients infected with H5N1 in updated guidance published on the WHO website today. Experts believe that a human influenza pandemic is (...) |
| 2007-08-22: |
SemBioSys Updates Apo AI Development Program
Calgary, Canada ( PRN/ots ) - - Canadian Biotechnology Company Confirms Commercial Expression Levels of Apo AI Milano Variant and Clarifies Status of Native Apo AI SemBioSys Genetics Inc. ( TSX:SBS ), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, (...) |
| 2007-08-20: |
Wyeth Receives Approval from European Medicines Agency for New BeneFix Features
Maidenhead, England ( PRN/ots ) - - Enhancements Provide Haemophilia B Patients with a Simpler and More Convenient Preparation Process for Recombinant Factor IX - Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), announced today that it has received approval from the European Medicines Agency (...) |
| 2007-08-09: |
Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
New York ( PRN/ots ) - Callisto Pharmaceuticals, Inc. ( Amex: KAL; FWB: CA4 ), a developer of new drug treatments in the fight against cancer and inflammatory diseases, announced today the addition of two sites to its Phase II clinical trial of Atiprimod to treat (...) |
| 2007-08-02: |
FDA Allows Long Term Use of ISA247 in Isotechnika Phase 2b Kidney Transplant Trial
Edmonton, Canada ( PRN/ots ) - Isotechnika today announced that the Company has received permission from the Food and Drug Administration of the United States ( FDA ) for the long term use of ISA247 in patients currently participating in the Company's Phase 2b kidney transplant ( PROMISE ) trial. (...) |
| 2007-08-01: |
MDS Pharma Services Expands Development & Regulatory Services in Europe
King Of Prussia, Pennsylvania ( PRN/ots ) - MDS Pharma Services, a leading provider of innovative drug discovery and development solutions, announced today the expansion of its Development & Regulatory Services ( DRS ) business in Europe. MDS Pharma Services will now offer full - service DRS consulting services to (...) |
| 2007-08-01: |
EMEA Committee Recommends Orphan Medicinal Product Designation for ISA247 for the Treatment of Uveitis
Edmonton, Canada ( PRN/ots ) - Isotechnika Inc. ( TSX:ISA ) announced today that the European Agency for the Evaluation of Medicinal Products ( EMEA ) committee for Orphan Medicinal Products has adopted a positive opinion on orphan medicinal product designation for ISA247 for the treatment of chronic, non - (...) |
| 2007-08-01: |
Eslax( R ) ( Rocuronium Bromide ) Approved in Japan
Oss, The Netherlands ( PRN/ots ) - Organon, the human healthcare business unit of Akzo Nobel ( Euronext Amsterdam: AKZ ), today announced that the Japanese Ministry of Health, Labour and Welfare ( MHLW ) has approved rocuronium bromide, its neuromuscular blocking agent ( NMBA ) for use during general anesthesia, under (...) |
| 2007-07-31: |
AGA Medical Wins Patent Infringement Lawsuit Against Occlutech GmbH
Minneapolis ( PRN/ots ) - AGA Medical Corporation ( "AGA" ) today announced that it has won its patent infringement lawsuit against Occlutech GmbH, headquartered in Jena, Germany, and DRABO Medizintechnik, located in Cologne, Germany. AGA is the owner of a European patent ( EP 0 808 (...) |
| 2007-07-31: |
Takeda Responds to the FDA Advisory Committee Recommendation
London ( PRN/ots ) - Following a joint meeting today of the U.S. Food and Drug Administration ( FDA ) Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Takeda Global Research & Development ( TGRD ) underscores its position that ACTOS( R ) ( pioglitazone (...) |
| 2007-07-26: |
MIRCERA Approved in European Union for Treatment of Anaemia Related to Chronic Kidney Disease
Basel, Switzerland ( PRN/ots ) - - First Anti - Anaemia Product Offering Simple Once - Monthly Maintenance Treatment Roche announced today that the European Commission has approved its innovative drug MIRCERA to treat anaemia associated with chronic kidney disease ( CKD ). The approval of MIRCERA results in (...) |
| 2007-07-25: |
New SPIRIVA( R ) Respimat( R ) Inhaler Completes European Approval Process for COPD
Ingelheim, Germany ( PRN/ots ) - - Patients to Benefit From Easy - to - Use Inhaler With Enhanced Drug Delivery Boehringer Ingelheim and Pfizer today announced successful completion of the approval process for authorisation to market SPIRIVA( R ) Respimat( R ) in the European Union for people with chronic obstructive (...) |
| 2007-07-24: |
Boehringer Ingelheim Announces First International Head - to - Head Trial of Aptivus( R ) ( tipranavir ) versus darunavir in Treatment - Experienced HIV - Positive Patients
Ingelheim, Germany ( PRN/ots ) - - Trial to compare newest protease inhibitors in treatment - experienced patients with resistance to more than one PI Boehringer Ingelheim GmbH announced today that enrollment of the POTENT study will begin in August 2007. POTENT will compare the efficacy (...) |
| 2007-07-23: |
Isotechnika Completes Patient Recruitment of Pivotal Phase 3 Psoriasis Trial
Edmonton, Canada ( PRN/ots ) - Isotechnika Inc. ( TSX:ISA ) announced today that the Company has completed recruitment of its pivotal Phase 3 European/Canadian psoriasis trial ( ESSENCE ). As of July 20, 2007, the Company closed recruitment at 638 patients. The patient population is made up (...) |
| 2007-07-23: |
European Survey to Gain Insight into Treatment - Experienced Patients' Perspectives on Living with HIV
Sydney, Australia ( PRN/ots ) - Recent launches of new protease inhibitors and the anticipated availability of new antiretroviral drug classes have increased the therapeutic options available to treatment - experienced HIV - positive patients, and made achieving an undetectable viral load a realistic goal for this (...) |
| 2007-07-23: |
International Experts and Women Living With HIV Discuss Urgent Needs of HIV - Positive Women at International AIDS Society ( IAS ) Congress
Sydney, Australia ( PRN/ots ) - - Panelists Available For Interviews - For Immediate Release: Webcast Will Be Available At: Http://Link.Viostream.Com/?A02deceb - Ecf4 - 4d9f - 9118 - F5f60faef629 Women Living Positive, a roundtable discussion at the IAS congress in Sydney, featured the perspectives of (...) |
| 2007-07-20: |
Avastin( R ) Receives Positive Opinion in Europe for First - Line Treatment of Patients With Advanced Lung Cancer
Basel, Switzerland ( PRN/ots ) - - First Medicine Shown to Extend Survival of Previously Untreated Patients Beyond One Year Roche announced today that the European Committee for Medicinal Products for Human Use ( CHMP ) has issued a positive recommendation for the first - line use of (...) |
|
|
back...
1
2
3
4
5
6
7
8
9
10
11
more... |
